Order Article Reprints

Doheny D, Manore S, Sirkisoon SR, Zhu D, Aguayo NR, Harrison A, Najjar M, Anguelov M, Cox AO, Furdui CM, et al. An FDA-Approved Antifungal, Ketoconazole, and Its Novel Derivative Suppress tGLI1-Mediated Breast Cancer Brain Metastasis by Inhibiting the DNA-Binding Activity of Brain Metastasis-Promoting Transcription Factor tGLI1. Cancers. 2022; 14(17):4256. https://doi.org/10.3390/cancers14174256

Doheny, Daniel, Sara Manore, Sherona R. Sirkisoon, Dongqin Zhu, Noah R. Aguayo, Alexandria Harrison, Mariana Najjar, Marlyn Anguelov, Anderson O’Brien Cox, Cristina M. Furdui, and et al. 2022. "An FDA-Approved Antifungal, Ketoconazole, and Its Novel Derivative Suppress tGLI1-Mediated Breast Cancer Brain Metastasis by Inhibiting the DNA-Binding Activity of Brain Metastasis-Promoting Transcription Factor tGLI1" Cancers 14, no. 17: 4256. https://doi.org/10.3390/cancers14174256

Doheny, D., Manore, S., Sirkisoon, S. R., Zhu, D., Aguayo, N. R., Harrison, A., Najjar, M., Anguelov, M., Cox, A. O., Furdui, C. M., Watabe, K., Hollis, T., Thomas, A., Strowd, R., & Lo, H.-W. (2022). An FDA-Approved Antifungal, Ketoconazole, and Its Novel Derivative Suppress tGLI1-Mediated Breast Cancer Brain Metastasis by Inhibiting the DNA-Binding Activity of Brain Metastasis-Promoting Transcription Factor tGLI1. Cancers, 14(17), 4256. https://doi.org/10.3390/cancers14174256